Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period ending May 28, 2025. The report primarily addresses the outcome of an interim analysis for the Phase 3 clinical trial of vilobelimab in the treatment of pyoderma gangrenosum.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes and strategic resource allocation rather than financial performance data.
Material Changes
- Pyoderma Gangrenosum Trial: The Independent Data Monitoring Committee recommended stopping the Phase 3 trial of vilobelimab for pyoderma gangrenosum due to futility based on data from the first 30 enrolled patients.
- Strategic Pivot: The Company intends to discontinue further development of vilobelimab in the pyoderma gangrenosum indication.
- Resource Reallocation: Resources will be prioritized for INF904, with Phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa anticipated in the summer of 2025.
- Safety Profile: No unexpected adverse events were noted during the interim analysis of the pyoderma gangrenosum study.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- GOHIBIC (vilobelimab): Remains available in the U.S. under Emergency Use Authorization for hospitalized COVID-19 adults requiring invasive mechanical ventilation or ECMO. In the EU, it holds marketing authorization under exceptional circumstances for SARS-CoV-2-induced acute respiratory distress syndrome.
- BARDA Study: The Company will continue supporting the BARDA-funded Phase 2 clinical platform study.
- INF904: Anticipated Phase 2a data readouts for chronic spontaneous urticaria and hidradenitis suppurativa are expected this summer.
Risks and Contingencies:
- The filing includes standard forward-looking statements regarding risks, uncertainties, and factors that could cause actual results to differ materially from projections.
- The discontinuation of the pyoderma gangrenosum program represents a significant reduction in the potential commercial scope of vilobelimab.
Investor Verification Checklist
- Verify the specific timeline for the anticipated summer 2025 Phase 2a data readouts for INF904.
- Confirm the current cash runway and burn rate following the decision to discontinue the pyoderma gangrenosum program.
- Review the terms of the BARDA-funded Phase 2 clinical platform study to understand ongoing funding obligations.
- Assess the impact of the futility finding on the overall valuation and future regulatory strategy for vilobelimab.